ST-2; a Non-invasive Fibrosis Marker for Chronic Hepatitis B

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2012 by Turkiye Yuksek Ihtisas Education and Research Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
İsmail Hakkı KALKAN, Turkiye Yuksek Ihtisas Education and Research Hospital
ClinicalTrials.gov Identifier:
NCT01633554
First received: July 1, 2012
Last updated: July 3, 2012
Last verified: July 2012

July 1, 2012
July 3, 2012
January 2011
July 2012   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01633554 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
ST-2; a Non-invasive Fibrosis Marker for Chronic Hepatitis B
The Ability of Prediction of Fibrosis for ST-2 as a Non-invasive Marker in Chronic Hepatitis B

IL-33 is a recently identified number of the IL-1 family. Hepatic over-expression of IL-33 has been recently linked to liver fibrosis. ST-2 exerts pro-inflammatory effects of IL-33. We aimed to determine ability of ST2 to predict fibrosis in chronic hepatitis B.

ST-2 is an IL-1 receptor family member and exists in both a membrane-bound isoform and a soluble (sST2) isoform. It has a functional ligand (Interleukin-33) and via ST-2/IL-33 inflammation and immunity is regulated. Hepatic over-expression of IL-33 has been recently linked to liver fibrosis. ST-2 exerts pro-inflammatory effects of IL-33. We aimed to determine ability of ST2 to predict fibrosis in chronic hepatitis B.

Observational
Observational Model: Case Control
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample

25 Healthy Volunteers 45 patients with chronic hepatitis B 25 patients with liver cirrhosis

Sequela of Chronic Liver Disease
Not Provided
  • Chronic Hepatitis B Group
    Patients with chronic hepatitis B
  • Cirrhosis
    Patients with liver cirrhosis
  • Control Group
    Control Group: Healthy Volunteers
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
95
September 2012
July 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Clinical diagnosis of chronic hepatitis B or liver cirrhosis

Exclusion Criteria:

  • Accompanying chronic inflammatory disease
Both
18 Years and older
Yes
Contact: İsmail H KALKAN, MD +90 312 437 67 78 drismailster@gmail.com
Turkey
 
NCT01633554
24190708, IKalkan24190708
Yes
İsmail Hakkı KALKAN, Turkiye Yuksek Ihtisas Education and Research Hospital
Turkiye Yuksek Ihtisas Education and Research Hospital
Not Provided
Not Provided
Turkiye Yuksek Ihtisas Education and Research Hospital
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP